Dr. Andrews

David W. Andrews, MD

Contact Dr. Andrews

909 Walnut Street
COB, 2nd Floor
Philadelphia, PA 19107

(215) 955-7000
(215) 503-7038 fax

Publications for this author are currently unavailable.

Medical School

BS, Biological Science, Stanford University - 1975
BA, Political Science, Stanford University - 1975
MS, Biological Science, Stanford University - 1977
MD, University of Colorado - 1983


Cornell Medical Center - New York Hospital


Memorial Sloan-Kettering Cancer Center, NY

Board Certification

Neurological Surgery

Hospital Appointment

Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

Anthony Alfred Chiurco Professor of Neurological Surgery

Associate Training Program Director

Director, Division of Neuro-oncologic Neurosurgery and Stereotactic Radiosurgery

Director, Stereotactic Radiosurgery Units, Jefferson Hospital for Neuroscience

Expertise and Research Interests

Subspecialization in:

  • Surgical and radiosurgical treatment of brain tumors
  • Neuro-oncologic neurosurgery with image-guidance and intraoperative motor and speech corticography
  • Neuroendoscopic neurosurgery
  • Biologically-based treatment of malignant gliomas
  • MRI-based stereotactic biopsy
  • Conventional fraction stereotactic radiotherapy

Dr. Andrews trained at the New York Hospital-Cornell Medical Center and completed a one year fellowship in Neuro-oncology at the Memorial Sloan-Kettering Cancer Center. At the inception of his academic career, he received a prestigious Physician Scientist Award conferred by the National Cancer Institute to pursue basic research devoted to the molecular biology of gliomas for a 5 year period. His mentor was Dr. Carlo Croce, a member of the National Academy of Science and one of the leading cancer researches in America today.

Drawing from his background in molecular biology, Dr. Andrews was the first physician at Thomas Jefferson University and in the Delaware Valley to participate in a prospective randomized trial involving gene therapy trial for the treatment of glioma which closed in 1999. Dr. Andrews currently serves as Co-Principal Investigator of a unique FDA-approved antisense DNA protocol designed for the treatment of glioma and has thus far successfully treated 12 patients. With this Phase I study still open, he has submitted four additional Phase I through Phase III proposals to the FDA for approval based on the early promising results in the Phase I trial.

Dr Andrews is recognized as a world leader in radiosurgery and established the first Radiosurgery Program in the Delaware Valley in 1991. He has lectured throughout the world as an invited speaker on radiosurgery topics and is noted for techniques in stereotactic radiotherapy which he has pioneered and has described successful treatments of tumors involving or near special sensory nerves such as the optic nerve or cochlear nerve.

Invited Lectures :

  • 1993 Hospital Princesa, Madrid, Spain, Inauguration of Radiosurgery in Spain
  • 1994 Barcelona, Spain, Inauguration of Radiosurgery in Barcelona (panelist)
  • 1994 Madrid, Spain, First Spanish Stereotactic Radiosurgery Congress
  • 1994 Philadelphia, PA, the Pan-Philadelphia Neurosurgery Conference
  • 1995 Salzburg, Austria, The Cornell-Austrian Seminars in Medicine
  • 1995 Mexico City, Mexico, The Neuroscience Institute
  • 1995 Gainesville, FL, The Second X-Knife Society Meeting
  • 1995 Taipei, Taiwan, the Australo-Asian Neurosurgery Congress
  • 1996 The Mayo Clinic, Rochester, MN
  • 1996 Paris, France, The French Neurosurgery Congress
  • 1996 Philadelphia, PA, The Third X-Knife Society Meeting
  • 1997 Madrid, Spain, The Third Biannual International Stereotactic Radiosurgery Society (panelist)
  • 1997 Orlando, FL, The Fourth X-Knife Society Meeting
  • 1997 San Francisco, CA, Joint AANS-CNS Course on Functional and Stereotactic Neurosurgery (faculty)
  • 1998 Bangkok, Thailand, Inauguration of Radiosurgery in Thailand
  • 1998 Snowmass, Colorado, The Mayfield Clinic-Cleveland Clinic Winter Neuroscience Symposium (faculty)
  • 1999 Sydney, Australia, The Fourth Biannual International Stereotactic Radiosurgery Society (panelist)
  • 1999 Allentown, PA, Inauguration and Continuing Education Course/ Radiosurgery, Lehigh Valley Hospital
  • 1999 Barcelona (Sitges), Spain, The Second Spanish Radiosurgery Society (panelist)
  • 1999 Milwaukee, WS, Biannual Acoustic Neuroma Association (panelist/lecturer)
  • 1999 Snowbird, UT, The American Society of Functional and Stereotactic Radiosurgery (panelist)
  • 1999 Boston, MA, The Congress of Neurological Surgery (panelist)
  • 2000 Snowmass, CO, The Mayfield Clinic-Cleveland Clinic Winter Neuroscience Symposium (faculty)
  • 2000 Munich, Germany, Klinicum Grosshaden
  • 2000 San Antonio, TX, The Congress of Neurological Surgery (faculty)
  • 2000 Sao Paolo, Brazil Radiosurgery Symposium (faculty/ Visiting Professor)

In addition to successfully eliminating tumors, the fractionated stereotactic technique also preserves sight and hearing. He was recently invited to speak before the Acoustic Neuroma Association in Milwaukie to share his experience of fractionated stereotactic radiotherapy with acoustic tumor patients. He is Principal Investigator of a North American prospective radiosurgery randomized trial sponsored by the RTOG and the National Cancer Institute examining patients with brain metastases that has accrued over 300 patients from 60 different participating institutions.

Dr. Andrews is a member of the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, the American and World Societies of Functional And Stereotactic Neurosurgery, the International Stereotactic Radiosurgery Society, and the Society of University Neurosurgeons.


Neurosurgery; neuro-oncology; radiosurgery; gamma knife; LINAC; brain tumor